NCT05606367招募中不适用
A Prospective, Randomized, Multicenter Clinical Trial of Non-slip Balloon Catheter in Patients With Coronary Artery Stenosis
Shanghai MicroPort Rhythm MedTech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年1月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Acute Lumen Gain
研究概览
简要总结
This is a prospective, multicenter, randomized controlled clinical investigation aiming to evaluate the safety and effectiveness of non-slip balloon catheter for the treatment of patients with coronary artery stenosis.
详细描述
This trial is a prospective, multicenter, randomized controlled clinical trial. 200 subjects are expected to be recruited in 7 research centers in China and randomly divided into two groups according to the ratio of test group: control group = 1:1. The primary endpoint is the acute lumen gain.
All subjects receive clinical follow-up during hospitalization and 30 days after surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Inclusion Criteria:
- •Subjects aged≥18 years.
- •Subjects with silent myocardial ischemia, symptomatic angina pectoris, or old myocardial infarction.
- •Subjects who can undergo percutaneous coronary intervention (PCI).
- •Subjects who are able to understand the purpose of the trial, participate voluntarily and indicate by signing the informed consent form that they recognize the risks and benefits described in the informed consent document and are willing to undergo clinical follow-up.
- •Angiography Inclusion Criteria:
- •For subjects with single or double lesions, revascularization is required for up to two lesions; at most one non-target lesion can be treated in the same period, and the target lesion can be treated only after the treatment of non-target lesion meets the angiography success criteria and there is no complication. Target and non-target lesions must be located in different major epicardial vessels.
- •Target lesion meets criteria for revascularization:
- •≥ 70% and < 100% diameter stenosis; or
- •≥ 50% and < 70% diameter stenosis with clinical evidence of ischemia
- •Target lesion vessel diameter is between 2.0 mm and 4.0 mm (inclusive), target lesion length ≤ 30 mm.
- •Clinically judged to be the lesion that requires or is amenable to pretreatment with the study balloon catheter and that the study balloon catheter can pass after pre-dilatation.
排除标准
- •Subjects who present with AMI recently (within 7 days).
- •Subjects who plan to undergo rotational atherectomy, laser coronary atherectomy, cutting balloon during target lesion pretreatment.
- •Subjects who are scheduled for PCI or CABG within 1 month of the index procedure.
- •Subjects with history of ischemic stroke or transient ischemic attack within 3 months.
- •Subjects with bleeding tendency, active gastrointestinal ulcer, history of cerebral hemorrhage or subarachnoid hemorrhage, contraindications to antiplatelet agents and anticoagulant therapy, and inability to receive antithrombotic therapy within 6 months.
- •Subjects who are scheduled for additional surgical procedures requiring discontinuation of aspirin, clopidogrel within 6 months of the baseline procedure.
- •Subjects with severe heart failure (NYHA III and above) or left ventricular ejection fraction(LVEF) < 35% (ultrasound or left ventriculography) and/or hemodynamic instability.
- •Subjects with unstable arrhythmias, such as high-risk premature ventricular contractions, ventricular tachycardia, high-grade atrioventricular block.
- •Subjects who are unable to receive antiplatelet therapy.
- •Subjects with hypersensitivity to aspirin, heparin, contrast agent, cobalt-based alloys (including metal elements such as cobalt, chromium, nickel, and tungsten), and polytetrafluoroethylene.
- •Subjects with renal insufficiency, serum creatinine greater than 177 μmol/L (2.0 mg/dl) or who are receiving hemodialysis.
- •Subjects who have been diagnosed with the terminal state of acute and chronic diseases such as advanced cancer and have a life expectancy of less than 1 year.
- •Subjects who have already received or are waiting for organ transplantation.
- •Subjects with blood routine test showed platelet count less than 50 × 10^9/L or more than 700 × 10^9/L, and/or hemoglobin less than 70 g/L.
- •Subjects who have participated in other clinical trials of drugs or medical devices before enrollment but have not been to the primary study endpoint until now.
- •Subjects who are judged by the investigator to be at high clinical risk for the use of the study device, unsuitable or non-compliant, and unable to complete the study as required.
- •Subjects who are pregnant or breastfeeding (women who may become pregnant must have a pregnancy test within 7 days prior to the baseline procedure).
- •Angiography Inclusion Criteria:
- •There are three severe lesions that needs revascularization.
- •Unprotected left main disease.
- •Target lesions meeting the following criteria:
- •Acute occlusion or thrombus;
- •Chronic total occlusion;
- •Bifurcation lesion;
- •Within 3 mm of the ostium of the left and right main coronary arteries (LAD/LCX/RCA);
- •CABG bridge stenosis;
- •Involved myocardial bridge;
- •Presence of dissection (Type C and above according to NHLBI classification);
- •Anatomy proximal to or within the target lesion that would preclude delivery of the study balloon catheter (e.g., severe tortuosity, etc.);
- •The study balloon catheter must pass previously implanted stent to reach target lesion.
结局指标
主要结局
Acute Lumen Gain
时间窗: Baseline procedure
Acute lumen gain is defined as the difference in the minimum lumen diameter of the target lesion before and after dilatation with the study balloon catheter (Microport or NSE Coronary Dilatation Catheter) as measured by QCA. (Acute lumen gain = minimum lumen diameter measured after dilatation with the study balloon catheter - minimum lumen diameter measured before dilatation with the study balloon catheter, AG=MLD post - MLD pre)
次要结局
- Procedural success(During hospitalization (up to 7 days after procedure))
- Device success(Baseline procedure)
- Lesion success(Baseline procedure)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza AInfluenza ANCT06205641Capital Medical University584
已完成
3 期
ArterX Surgical Sealant, A Randomized Prospective Multicenter TrialVascular DiseaseNCT00759681Tenaxis Medical, Inc.217
招募中
不适用
Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)Gastric CancerRecurrenceQuality of LifeNCT04740346National Cancer Center, Korea886
Unknown
不适用
Safety and Efficacy of Rotator Cuff Function Restoration Balloon in Irreparable Rotator Cuff TearRotator Cuff TearsNCT04538001Shanghai MicroPort Medical (Group) Co., Ltd.112
Unknown
不适用
Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV FistulaArteriovenous FistulaNCT04393688BrosMed Medical Co., Ltd168